[1]韩丽萍,陈莉明.GLP-1的神经保护作用[J].国际内分泌代谢杂志,2016,36(05):316-319.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
 Han Liping,Chen Liming.Neuroprotective actions of glucagon-like peptide-1[J].International Journal of Endocrinology and Metabolism,2016,36(05):316-319.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
点击复制

GLP-1的神经保护作用()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
36
期数:
2016年05期
页码:
316-319
栏目:
综述
出版日期:
2016-09-20

文章信息/Info

Title:
Neuroprotective actions of glucagon-like peptide-1
作者:
韩丽萍陈莉明
300070 天津医科大学代谢病医院神经内科
Author(s):
Han Liping Chen Liming
Department of Neurology, The Metabolic Disease Hospital of Tianjin Medical University, Tianjin 300070, China
关键词:
胰高血糖素样肽-1 胰高血糖素样肽-1受体 阿尔茨海默病 帕金森病 2型糖尿病
Keywords:
Glucagon-like peptide-1 Glucagon-like peptide-1 recepter Alzheimer's disease Pakinson's disease Type 2 diabetes mellitus
DOI:
10.3760/cma.j.issn.1673-4157.2016.05.08
摘要:
流行病学研究表明,2型糖尿病和神经变性疾病,包括阿尔茨海默病和帕金森病及缺血性脑血管病存在紧密联系。这些疾病都存在共同的病理生理学特征,包括氧化应激、胰岛素抵抗、异常蛋白的处理、认知功能的减退,目前尚无有效的治疗方案干预上述疾病。近年来,以胰高血糖素样肽-1(GLP-1)为基础的降糖药物备受关注。体内和体外研究表明,激活GLP-1受体可以促进神经细胞的增殖、分化和突起的生长、提高突触的可塑性和记忆的生成、调节神经细胞钙稳态,对于改善记忆功能障碍、神经运动障碍、缺血性脑血管损伤、氧化应激及视网膜退化等神经病变发挥重要作用。
Abstract:
Epidemiological data indicate an association between type 2 diabetes mellitus and most major neurodegenerative diseases, including Alzheimer's, Parkinson's diseases and ischemic cerebrovascular disease. Studies have revealed that these diseases have common pathophysiological features, including oxidative stress, insulin resistance, abnormal protein processing and cognitive decline. Nowadays there is no effective treatment of diseases mentioned above. Glucagon-like peptide-1(GLP-1)-based anti-diabetic drugs have drawn particular attention in recent years. In vivo and in vitro evidences supported that stimulation of GLP-1 receptor might promote neuronal cell proliferation, differentiation and neurite outgrowth, enhance synaptic plasticity and memory formation, regulate calcium homeostasis, and play an important role in improving memory dysfunction, neuromotor impairment, ischemic cerebrovascular damage, oxidative stress,retinal degeneration and other diseases of the nervous system.

参考文献/References:

[1] Salcedo I, Tweedie D, Li Y, et al. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders[J].Br J Pharmacol,2012,166(5):1586-1599. DOI: 10.1111/j.1476-5381.2012.01971.x.
[2] Akter K, Lanza EA, Martin SA, et al. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment [J].Br J Clin Pharmacol,2011,71(3):365-376. DOI: 10.1111/j.1365-2125.2010.03830.x.
[3] Kappe C, Zhang Q, Nyström T,et al. Effects of high-fat diet and the anti-diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-cells[J].Diabetol Metab Syndr,2014,6:70.DOI: 10.1186/1758-5996-6-70.
[4] Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus[J].Nat Rev Endocrinol,2009,5(5):262-269. DOI: 10.1038/nrendo.2009.48.
[5] Hamilton A, Hölscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system[J].Neuroreport,2009,20(13):1161-1166.DOI: 10.1097/WNR.0b013e32832fbf14.
[6] Belsham DD, Fick LJ, Dalvi PS, et al. Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons[J].FASEB J,2009,23(12):4256-4265. DOI: 10.1096/fj.09-133454.
[7] Hamilton A, Patterson S, Porter D,et al. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain[J].J Neurosci Res,2011,89(4):481-489. DOI: 10.1002/jnr.22565.
[8] Isacson R, Nielsen E, Dannaeus K, et al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test[J].Eur J Pharmacol,2011,650(1):249-255. DOI: 10.1016/j.ejphar.2010.10.008.
[9] Li H, Lee CH, Yoo KY, et al. Chronic treatment of exendin-4 affects cell proliferation and neuroblast differentiation in the adult mouse hippocampal dentate gyrus[J].Neurosci Lett,2010,486(1):38-42. DOI: 10.1016/j.neulet.2010.09.040.
[10] Luciani P, Deledda C, Benvenuti S,et al. Exendin-4 induces cell adhesion and differentiation and counteracts the invasive potential of human neuroblastoma cells[J].PLoS One,2013,8(8):e71716. DOI: 10.1371/journal.pone.0071716.
[11] McClean PL, Parthsarathy V, Faivre E, et al. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease[J].J Neurosci,2011,31(17):6587-6594. DOI: 10.1523/JNEUROSCI.0529-11.2011.
[12] Abbas T, Faivre E, Hölscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease[J].Behav Brain Res,2009,205(1):265-271. DOI: 10.1016/j.bbr.2009.06.035.
[13] Li LH, Tian XR, Hu ZP. The key target of neuroprotection after the onset of ischemic stroke: secretory pathway Ca(2+)-ATPase 1[J].Neural Regen Res,2015,10(8):1271-1278. DOI:10.4103/1673-5374.162760.
[14] Bao Y, Jiang L, Chen H,et al. The neuroprotective effect of liraglutide is mediated by glucagon-like peptide 1 receptor-mediated activation of cAMP/PKA/CREB pathway[J].Cell Physiol Biochem,2015,36(6):2366-2378. DOI: 10.1159/000430199.
[15] O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease[J].Annu Rev Neurosci,2011,34:185-204. DOI: 10.1146/annurev-neuro-061010-113613.
[16] Marchetti C, Marie H. Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models [J].Rev Neurosci,2011,22(4):373-402. DOI: 10.1515/RNS.2011.035.
[17] Gengler S, McClean PL, McCurtin R,et al. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice[J].Neurobiol Aging,2012,33(2):265-276. DOI: 10.1016/j.neurobiolaging.2010.02.014.
[18] Li L, Zhang ZF, Holscher C, et al.(Val )glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains[J].Eur J Pharmacol,2012,674(2-3):280-286. DOI: 10.1016/j.ejphar.2011.11.005.
[19] Kim S, Moon M, Park S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3expression in an animal model of Parkinson's disease[J].J Endocrinol,2009,202(3):431-439. DOI: 10.1677/JOE-09-0132.
[20] Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and parkinsonism[J].Proc Natl Acad Sci U S A,2009,106(4):1285-1290. DOI: 10.1073/pnas.0806720106.
[21] Jolivalt CG, Fineman M, Deacon CF, et al. GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice[J].Diabetes Obes Metab,2011,13(11):990-1000. DOI: 10.1111/j.1463-1326.2011.01431.x.
[22] Kan M, Guo G, Singh B, et al. Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy[J].J Neuropathol Exp Neurol,2012,71(6):494-510. DOI: 10.1097/NEN.0b013e3182580673.
[23] Martin B, Golden E, Carlson OD, et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease[J].Diabetes,2009,58(2):318-328. DOI: 10.2337/db08-0799.
[24] Teramoto S, Miyamoto N, Yatomi K,et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia[J].J Cereb Blood Flow Metab,2011,31(8):1696-1705. DOI: 10.1038/jcbfm.2011.51.
[25] Liu JH, Yin F, Guo LX,et al. Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway[J].Acta Pharmacol Sin,2009,30(2):159-165. DOI: 10.1038/aps.2008.25.
[26] Zhang Y, Zhang J, Wang Q, et al. Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats[J].Invest Ophthalmol Vis Sci,2011,52(1):278-285.DOI: 10.1167/iovs.09-4727.
[27] Zhang R, Zhang H, Xu L, et al. Neuroprotective effect of intravitreal cell-based glucagon-like peptide-1 production in the optic nerve crush model[J].Acta Ophthalmol,2011,89(4):e320-e326. DOI: 10.1111/j.1755-3768.2010.02044.x.

相似文献/References:

[1]姚红,郗光霞,郭敏,等.胰高血糖素样肽-1及其受体在中枢神经系统的分布和功能[J].国际内分泌代谢杂志,2014,(01):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
 Yao Hong*,Xi Guangxia,Guo Min,et al.The distributions and functions of glucagon like peptide-1 and its receptors in the central nervous system[J].International Journal of Endocrinology and Metabolism,2014,(05):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
[2]黄婷婷,沈飞霞,谷雪梅.胰高血糖素样肽-1与骨骼肌葡萄糖代谢[J].国际内分泌代谢杂志,2014,(04):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
 Huang Tingting,Shen Feixia,Gu Xuemei..Glucagon-like peptide-1 and glucose metabolism in the skeletal muscle[J].International Journal of Endocrinology and Metabolism,2014,(05):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
[3]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
 Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[4]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
 Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(05):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[5]吴海洋,黄祯子,彭嘉欣,等.胰高血糖素样肽-1与肾素-血管紧张素系统的交互作用[J].国际内分泌代谢杂志,2016,36(05):312.[doi:10.3760/cma.j.issn.1673-4157.2016.05.07]
 Wu Haiyang,Huang Zhen-zi,Peng Jiaxin,et al.Interaction between glucagon-like peptide-1 and renin angiotensin system[J].International Journal of Endocrinology and Metabolism,2016,36(05):312.[doi:10.3760/cma.j.issn.1673-4157.2016.05.07]
[6]林楚曼 林伟浩 周蕊 杨力.GLP-1缓解非酒精性脂肪性肝病相关信号通路的研究进展[J].国际内分泌代谢杂志,2018,38(03):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
 Lin Chuman*,Lin Weihao,Zhou Rui,et al.The research progresses on GLP-1 related signal pathways in alleviating non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2018,38(05):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
[7]阮莹莹 闫彩凤.GLP-1对2型糖尿病患者骨骼的影响[J].国际内分泌代谢杂志,2018,38(04):275.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
 Ruan Yingying,Yan Caifeng..The impact of GLP-1 on bone in patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2018,38(05):275.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
[8]王永 乐岭.GLP-1对血管重构中血管平滑肌细胞的影响[J].国际内分泌代谢杂志,2018,38(01):23.[doi:10.3760/cma.j.issn.1673-4157.2018.01.006]
 Wang Yong,Yue Ling.Effects of GLP-1 on vascular smooth muscle cells in vascular remodeling[J].International Journal of Endocrinology and Metabolism,2018,38(05):23.[doi:10.3760/cma.j.issn.1673-4157.2018.01.006]
[9]史雨清,杨昱,李宸,等.Tirzepatide:一种新型GLP-1/GIP双受体激动剂[J].国际内分泌代谢杂志,2021,41(06):645.[doi:10.3760/cma.j.cn121383-20200924-09046]
 Shi Yuqing,Yang Yu,Li Chen,et al.Tirzepatide:a novel GLP-1/GIP dual receptor agonist[J].International Journal of Endocrinology and Metabolism,2021,41(05):645.[doi:10.3760/cma.j.cn121383-20200924-09046]

备注/Memo

备注/Memo:
通信作者:陈莉明,Email: xfx22081@vip.163.com
更新日期/Last Update: 2016-11-20